Techno Drugs Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 1/6
Techno Drugs's earnings have been declining at an average annual rate of -59.3%, while the Pharmaceuticals industry saw earnings growing at 10.3% annually. Revenues have been declining at an average rate of 45.6% per year. Techno Drugs's return on equity is 7.5%, and it has net margins of 7.2%.
Anahtar bilgiler
-59.3%
Kazanç büyüme oranı
-59.3%
EPS büyüme oranı
| Pharmaceuticals Sektör Büyümesi | 11.0% |
| Gelir büyüme oranı | -45.6% |
| Özkaynak getirisi | 7.5% |
| Net Marj | 7.2% |
| Son Kazanç Güncellemesi | 30 Jun 2023 |
Yakın geçmiş performans güncellemeleri
Recent updates
Gelir ve Gider Dağılımı
Techno Drugs nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 30 Jun 23 | 2,733 | 196 | 628 | 0 |
| 30 Jun 22 | 5,029 | 480 | 905 | 0 |
Kaliteli Kazançlar: TECHNODRUG has high quality earnings.
Büyüyen Kar Marjı: TECHNODRUG's current net profit margins (7.2%) are lower than last year (9.5%).
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: Insufficient data to determine if TECHNODRUG's year-on-year earnings growth rate was positive over the past 5 years.
Büyüme Hızlandırma: TECHNODRUG's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Kazançlar vs. Sektör: TECHNODRUG had negative earnings growth (-59.3%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-2.8%).
Özkaynak Getirisi
Yüksek ROE: TECHNODRUG's Return on Equity (7.5%) is considered low.